ROSWELL PARK CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Calcitriol, Ketoconazole, and Dexamethasone in Treating Patients With Metastatic or Unresectable Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2005-10-13

Last Posted Date: 2013-01-31

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 15

Registration Number: NCT00238225

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Selenium in Treating Patients Who Are Undergoing Brachytherapy for Stage I or Stage II Prostate Cancer

Phase 1

Completed

Conditions: Prostate Cancer

Interventions: Other: placebo
Drug: selenium

First Posted Date: 2005-09-22

Last Posted Date: 2012-02-09

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 18

Registration Number: NCT00217516

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Paricalcitol and Gemcitabine in Treating Patients With Advanced Cancer

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: gemcitabine hydrochloride
Drug: paricalcitol

First Posted Date: 2005-09-22

Last Posted Date: 2014-12-09

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 34

Registration Number: NCT00217477

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Fulvestrant in Treating Patients With Recurrent Prostate Cancer

Phase 2

Terminated

Conditions: Prostate Cancer

Interventions: Drug: fulvestrant

First Posted Date: 2005-09-22

Last Posted Date: 2015-04-16

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 17

Registration Number: NCT00217464

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Irinotecan and Gemcitabine in Treating Patients With Recurrent or Progressive Stage III or Stage IV Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

First Posted Date: 2005-09-16

Last Posted Date: 2012-03-06

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 38

Registration Number: NCT00182806

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Irinotecan and Selenium in Treating Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2005-06-03

Last Posted Date: 2014-01-13

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 36

Registration Number: NCT00112892

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Bevacizumab and Capecitabine as First-Line Therapy in Treating Older Patients With Metastatic Colorectal Cancer

Phase 2

Terminated

Conditions: Colorectal Cancer

Interventions: Biological: bevacizumab
Drug: capecitabine

First Posted Date: 2005-04-06

Last Posted Date: 2014-07-04

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 16

Registration Number: NCT00107315

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Gemcitabine, Capecitabine, and Bevacizumab in Treating Patients With Metastatic or Unresectable Pancreatic Cancer

Phase 2

Completed

Conditions: Pancreatic Cancer

First Posted Date: 2005-01-07

Last Posted Date: 2015-12-24

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 50

Registration Number: NCT00100815

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸
Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Fludarabine and Thalidomide in Treating Patients With Newly Diagnosed Chronic Lymphocytic Leukemia

Phase 1

Completed

Conditions: Leukemia

Interventions: Drug: fludarabine phosphate
Drug: thalidomide

First Posted Date: 2004-11-09

Last Posted Date: 2013-10-24

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 43

Registration Number: NCT00096018

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Lenalidomide With or Without Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Phase 2

Completed

Conditions: Leukemia

Interventions: Biological: rituximab
Drug: lenalidomide

First Posted Date: 2004-11-09

Last Posted Date: 2017-07-11

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 45

Registration Number: NCT00096044

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy